News & Trends

• 042026-09

  Salubris' Global First ARNI-Based Combination Antihypertensive Drug Clinical Data Presented at ESC 2026

• 102026-08

  Salubris’Innovative siRNA Drug SAL0195 Approved for Clinical Trials for Elevated Lipoprotein(a)

• 232026-07

  Salubris Announces Acceptance of New Drug Application for Sacubitril/Ailsartan/Amlodipine Tablets

• 102026-07

  Salubris Receives NMPA Clinical Trial Approval for SAL0167,a Novel Cyclic Peptide Therapeutic Targeting Hyperlipidemia

• 222026-05

  Shenzhen Salubris Pharmaceuticals Receives Acceptance of Clinical Trial Application for Innovative siRNA Drug SAL0195 in Lipid-Related Diseases

• 172026-05

  Salubris’innovative biologic Xinfutai Plus® approved as the first onceweekly teriparatide formulation in China for the treatment of osteoporosis